Daito Pharmaceutical Co.,Ltd. [4577.T]
TOKYO, Jun 01 (Pulse News Wire) – Daito Pharmaceutical CO.,LTD. (4577.T) completed its share repurchase under the provisions of Company Law Article 178 on May 29, 2026.
The repurchased shares consisted of common stock totaling 1,242,000. Prior to the repurchase, these shares represented 4.1% of the outstanding shares. Following the completion of the repurchase, the total number of outstanding shares stands at 28,854,880.
Additionally, the post-repurchase self-held shares amount to 16,718. It should be noted that the figure for self-held shares does not include the company's own shares held within trust funds designated for employee stock grants, which total 94,340. This action was approved during a board meeting held on May 13, 2026, and executed on May 29, 2026.
The move reflects the company’s ongoing commitment to maintaining shareholder value through strategic capital management decisions.
🟢 Confidence: High AI-translated content.